sur Biophytis (EPA:ALBPS)
Biophytis Invites Shareholders to Upcoming General Meeting Amid Strategic Developments
Biophytis has announced its Ordinary and Extraordinary General Meeting scheduled for November 12, 2026, in Ivry-sur-Seine. The event coincides with significant progress in the company's lead drug candidate, BIO101, targeting obesity and sarcopenia.
The company is preparing to initiate the Phase 2 OBA clinical study for obesity, funded by a recent capital increase, with patient recruitment expected in early 2027. Concurrently, Biophytis is advancing its SARA-31 Phase 3 sarcopenia program through a joint venture in Hong Kong, aiming to propel BIO101's development in Asia.
Key resolutions will be presented, including a proposal for share consolidation to enhance market visibility. These resolutions aim to equip Biophytis with the necessary tools to continue its strategic development effectively, supporting shareholder interests without immediately increasing capital.
R. E.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Biophytis